Skip to main content
. 2021 Mar 3;13(5):1080. doi: 10.3390/cancers13051080
ADC directed antibody-drug conjugate
AKT the serine/threonine protein kinase
ALK Anaplastic lymphoma kinase
APC antigen presenting cells
ATF4 Activating Transcription Factor 4
BC breast cancer
BL1 basal-like 1
BL2 basal-like 2
BRCA BReast CAncer gene
CDK Cicline dependent kinase
CI confidance interval
CPS combined positive score
ECM extracellular matrix
EGFR Epidermal Growth Factor Receptor
EMA European Medicine Agency
ER estrogen receptor
ETM epithelial to mesenchymal transition
FAK focal adhesion kinase
G-CSF Granulocyte Colony-Stimulating Factor
GSIs γ -secretase inhibitors
HER2 epidermal growth factor receptor-2
HIF1 Hypoxia-Inducible Factor
HR hazard ratio
IFN-γ Interferon gamma
IGF-1R Insulin-like growth factor 1
IM immunomodulatory
JAK Janus-family tyrosine kinase
LAR luminal androgen receptor
M mesenchymal-like
MAPK Mitogen-activated protein kinase
MDSCs suppressor cells of myeloid derived origin
MET mesenchymal-epithelial transition factor
MSL mesenchymal stem cell-like
mTOR mammalian target of rapamycin
MVA Modified Vaccinia Ankara
NACT neoadjuvant chemotherapy
NSCLC no small cell lung cancer
ORR objective response rate
OS overall survival
PARP Poli ADP-ribose polymerase inhibitors
pCR pathological complete response
PD-1 programmed death-1
PDGF Platelet-Derived Growth Factor
PD-L1 Programmed Death-Ligand 1
PFS progression free survival
PI3K phosphatidylinositol-3-OH kinase
PR progesterone receptor
PTEN tensin homologue
RTKs Receptor tyrosine kinases
SFKs Src family kinases
SH Src homology
Src sarcoma oncogene cellular homolog
STAT Signal transducer and activator of transcription
TGF-β Tumor Necrosis Factor Beta
TKI tyrosine kynase inhibitor
TNBC triple negative breast cancer
TP53 Tumor protein53
Trop-2 trophoblast cell surface antigen-2
VEGF vascular endothelial growth factors